WHO fleshes out African and global lab capacity concerns
This article was originally published in Clinica
The WHO has acknowledged being concerned about the laboratory capacity of some countries in terms of meeting current influenza surveillance needs, saying that efforts to strengthen capacity are underway. "Surveillance is definitely not optimal everywhere in the world," said Keiji Fukuda, the WHO's interim assistant director-general for health security and the environment, during a press conference on July 7.
You may also be interested in...
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.